Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

NCT ID: NCT04478097

Last Updated: 2020-07-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-14
• Study Completion Date: 2021-01-01

Brief Summary

This study is a randomized, open, single-dose, 3 period partial replicated crossover-design study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy volunteers.

Detailed Description

To healthy subjects of fifty-one (51), following treatments are administered dosing in each period and wash-out period is a minimum of 14 days.

Conditions

Cardiovascular Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Reference-Reference-Test

Group Type: EXPERIMENTAL

CKD-330 Tab. and D086 Tab.

Intervention Type: DRUG

1T

CKD-333 Tab.

Intervention Type: DRUG

1T

Reference-Test-Reference

Group Type: EXPERIMENTAL

CKD-330 Tab. and D086 Tab.

Intervention Type: DRUG

1T

CKD-333 Tab.

Intervention Type: DRUG

1T

Test-Reference-Reference

Group Type: EXPERIMENTAL

CKD-330 Tab. and D086 Tab.

Intervention Type: DRUG

1T

CKD-333 Tab.

Intervention Type: DRUG

1T

Interventions

CKD-330 Tab. and D086 Tab.

1T

Intervention Type: DRUG

CKD-333 Tab.

1T

Intervention Type: DRUG

Other Intervention Names

Reference; Test

Eligibility Criteria

Inclusion Criteria

1. Healthy adults over the age of 19 years and under the age of 55 years at the time of screening

2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg

• BMI = Weight(kg)/ Height(m)2

3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years

4. Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/bacterial, etc.) and vital signs, ECG etc. performed at screening

5. Individuals who signed an informed consent form and decided to participate in the study after being fully informed of the study prior to participation

6. Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion

7. Individuals with the ability and willingness to participate the entire study period

Exclusion Criteria

1. Individuals with a medical evidence or a history of clinically significant hepatobiliary, renal, neurologic, respiratory, digestive, endocrine, blood-oncology, urinary, cardiovascular, musculoskeletal or psychiatric

2. Individuals with a medical history of gastrointestinal disease (e.g., Crohn's disease and ulcer) or gastrectomy (excluding simple appendectomy or herniotomy) that may affect drug absorption

3. Individuals with the following results at screening test:

• ALT or AST > 2x the upper limit of the normal range
• Creatinine > upper limit of the normal range or eGFR with MDRD <60 ml/min/1.73 m2
• ECG Result, QTc > 450msec
• CPK > UNL(upper normal limit) x 3.0
• K > 5.5mEq/l
• Hct < lower limit of the normal range

4. A history of regular alcohol consumption exceeding 21 units/week within the 3 months(1 unit = 10 g = 12.5 ml) prior to screening or individuals who cannot quit drinking from 48hr prior to the first dose to end of last blooding (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)

5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening or cannot quit smoking during hospitalization period

6. Individuals who had been administered investigational product(s) of other clinical study or bioequivalence study within the 6 months prior to the first dose of this study

7. Following vital signs results at screening

• Sitting systolic blood pressure ≥ 140 mmHg or < 90 mmHg
• sitting diastolic blood pressure ≥90 mmHg or <60 mmHg

8. Individuals with a medical history of significant drug abuse within one year prior to the screening or positive for abuse drug in urine test results at screening

9. Individuals taking medication known to significantly induce or inhibit drug metabolizing enzymes within 30days before the first administration of clinical trial drug

10. Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)

11. Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)

12. Individuals with hypersensitivity to investigational products or the investigational products ingredients

13. Patients or conditions deemed to be at risk for using investigational products

• Patient with hyperkalemia
• Patients with hepatopathy
• Patients with hereditary angioedema, ACE inhibitors or angiotensin 2 receptor antagonists who have a history of angioedema
• Primary hyperaldosteronism
• Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic obstructive cardiomyopathy
• Patients with ischemic heart disease, ischemic cardiovascular disease, cerebrovascular disease
• Patients with Intravascular volume depletion
• Patients with diabetes or kidney failure
• Patients with renal artery stenosis
• Patients with muscle disease
• Patients with Hypothyroidism
• Patients with a history of muscle toxicity when using statins or fibrates
• Patients who have recently had a kidney transplant
• Patients with history of shock

14. Individuals with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.

15. Individuals who drunk grapefruit juice or caffeine more than 5 cup per day within 3 months prior to screening or cannot quit drinking during clinical trials period

16. Individuals who cannot eat standard meal in institution

17. Women who are pregnant or may be pregnant

18. Individuals who were deemed to be inappropriate to participate in the study by the investigator

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 54 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Jang Hee Hong

Daejeon, , South Korea

Countries

South Korea

References

Kim JH, Song JH, Kim M, Hong JH, Sunwoo J, Jung JG. Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants. Adv Ther. 2024 Jul;41(7):2808-2825. doi: 10.1007/s12325-024-02869-y. Epub 2024 May 21.

Reference Type: DERIVED

PMID: 38771476 (View on PubMed)

Other Identifiers

A70_09BE2005

Identifier Type: -

Identifier Source: org_study_id